A comprehensive review of myelodysplastic syndrome patients with autoimmune diseases

References

• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114(5):937-51
   PubMed Web of Science ®Google Scholar
• Brunning RD, Orazi A, Germing U, Le Beau MM. Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Lee Harris N, et al. editors. WHO classification of tumours of haematopoietic and lympoid tissues. IARC Press; Lyon, France: 2008
   Google Scholar
• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89(6):2079-88
   PubMed Web of Science ®Google Scholar
• Park MJ, Kim HJ, Kim SH, et al. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS. Eur J Haematol 2008;81(5):364-73
   PubMed Web of Science ®Google Scholar
• Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108(2):419-25
   PubMed Web of Science ®Google Scholar
• Smith MA, McCaffrey RP, Karp JE. The secondary leukemias: challenges and research directions. J Natl Cancer Inst 1996;88(7):407-18
   PubMedGoogle Scholar
• Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003;102(1):43-52
   PubMed Web of Science ®Google Scholar
• Knipp S, Hildebrandt B, Richter J, et al. Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7. Haematologica 2005;90(5):691-3
   PubMed Web of Science ®Google Scholar
• Saif MW, Hopkins JL, Gore SD. Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leukemia & lymphoma 2002;43(11):2083-92
   PubMed Web of Science ®Google Scholar
• Enright H, Jacob HS, Vercellotti G, et al. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol 1995;91(2):403-8
   PubMed Web of Science ®Google Scholar
• Hamidou MA, Derenne S, Audrain MA, et al. Prevalence of rheumatic manifestations and antineutrophil cytoplasmic antibodies in haematological malignancies. A prospective study. Rheumatology 2000;39(4):417-20
   PubMed Web of Science ®Google Scholar
• Giannouli S, Voulgarelis M, Zintzaras E, et al. Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study. Rheumatology 2004;43(5):626-32
   PubMed Web of Science ®Google Scholar
• Hamidou MA, Boumalassa A, Larroche C, et al. Systemic medium-sized vessel vasculitis associated with chronic myelomonocytic leukemia. Semin Arthritis Rheum 2001;31(2):119-26
   PubMed Web of Science ®Google Scholar
• Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum 2007;57(8):1473-80
   PubMed Web of Science ®Google Scholar
• Marisavljevic D, Kraguljac N, Rolovic Z. Immunologic abnormalities in myelodysplastic syndromes: clinical features and characteristics of the lymphoid population. Med Oncol 2006;23(3):385-91
   PubMed Web of Science ®Google Scholar
• de Hollanda A, Beucher A, Henrion D, et al. Systemic and immune manifestations in myelodysplasia: a multicenter retrospective study. Arthritis Care Res 2011;63(8):1188-94
   PubMed Web of Science ®Google Scholar
• Okamoto T, Okada M, Mori A, et al. Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients. Int J Hematol 1997;66(3):345-51
   PubMed Web of Science ®Google Scholar
• Berthier S, Magy N, Gil H, et al. [Myelodysplasias and systemic diseases. A non-fortuitous association]. Rev Med Interne 2001;22(5):428-32
   PubMedGoogle Scholar
• Anderson LA, Pfeiffer RM, Landgren O, et al. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer 2009;100(5):822-8
   PubMed Web of Science ®Google Scholar
• Oguma S, Yoshida Y, Uchino H, et al. Clinical characteristics of Japanese patients with primary myelodysplastic syndromes: a co-operative study based on 838 cases. Anemia Study Group of the Ministry of Health and Welfare. Leuk Res 1995;19(3):219-25
   PubMed Web of Science ®Google Scholar
• Toyama K, Ohyashiki K, Yoshida Y, et al. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia 1993;7(4):499-508
   PubMed Web of Science ®Google Scholar
• Hamblin TJ. Immunological abnormalities in myelodysplastic syndromes. Semin Hematol 1996;33(2):150-62
   PubMed Web of Science ®Google Scholar
• Billstrom R, Johansson H, Johansson B, Mitelman F. Immune-mediated complications in patients with myelodysplastic syndromes – clinical and cytogenetic features. Eur J Haematol 1995;55(1):42-8
   PubMed Web of Science ®Google Scholar
• Castro M, Conn DL, Su WP, Garton JP. Rheumatic manifestations in myelodysplastic syndromes. J Rheumatol 1991;18(5):721-7
   PubMed Web of Science ®Google Scholar
• Dalamaga M, Karmaniolas K, Matekovits A, et al. Cutaneous manifestations in relation to immunologic parameters in a cohort of primary myelodysplastic syndrome patients. J Eur Acad Dermatol Venereol 2008;22(5):543-8
   PubMed Web of Science ®Google Scholar
• Espinosa G, Font J, Munoz-Rodriguez FJ, et al. Myelodysplastic and myeloproliferative syndromes associated with giant cell arteritis and polymyalgia rheumatica: a coincidental coexistence or a causal relationship? Clin Rheumatol 2002;21(4):309-13
   PubMed Web of Science ®Google Scholar
• Steurer M, Fritsche G, Tzankov A, et al. Large-vessel arteritis and myelodysplastic syndrome: report of two cases. Eur J Haematol 2004;73(2):128-33
   PubMed Web of Science ®Google Scholar
• Liozon E, Loustaud V, Fauchais AL, et al. Concurrent temporal (giant cell) arteritis and malignancy: report of 20 patients with review of the literature. J Rheumatol 2006;33(8):1606-14
   PubMed Web of Science ®Google Scholar
• Piette JC, Papo T, Chavanon P, et al. Myelodysplasia and relapsing polychondritis. J Rheumatol 1995;22(6):1208-9
   PubMed Web of Science ®Google Scholar
• Hebbar M, Brouillard M, Wattel E, et al. Association of myelodysplastic syndrome and relapsing polychondritis: further evidence. Leukemia 1995;9(4):731-3
   PubMed Web of Science ®Google Scholar
• Morioka N, Otsuka F, Nogita T, et al. Neutrophilic dermatosis with myelodysplastic syndrome: nuclear segmentation anomalies of neutrophils in the skin lesion and in peripheral blood. J Am Acad Dermatol 1990;23(2 Pt 1):247-9
   PubMed Web of Science ®Google Scholar
• Sokol RJ, Hewitt S, Booker DJ. Erythrocyte autoantibodies, autoimmune haemolysis, and myelodysplastic syndromes. J Clin Pathol 1989;42(10):1088-91
   PubMed Web of Science ®Google Scholar
• Economopoulos T, Economidou J, Giannopoulos G, et al. Immune abnormalities in myelodysplastic syndromes. J Clin Pathol 1985;38(8):908-11
   PubMed Web of Science ®Google Scholar
• Novaretti MC, Sopelete CR, Velloso ER, et al. Immunohematological findings in myelodysplastic syndrome. Acta Haematol 2001;105(1):1-6
   PubMed Web of Science ®Google Scholar
• Van Rhee F, Abela M. Coombs negative haemolytic anaemia responding to intravenous immunoglobulins in a patient with myelodysplastic syndrome. Clin Lab Haematol 1991;13(1):99-101
   PubMedGoogle Scholar
• Funato K, Kuriyama Y, Uchida Y, et al. Myelodysplastic syndrome accompanied by Addison’s disease and multiple autoimmune phenomena: steroid therapy resolved cytopenias and all immune disorders. Intern Med 2001;40(10):1041-4
   PubMed Web of Science ®Google Scholar
• Gupta R, Soupir CP, Johari V, Hasserjian RP. Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation. Br J Haematol 2007;139(2):265-8
   PubMed Web of Science ®Google Scholar
• Kimura S, Kuroda J, Akaogi T, et al. Trisomy 8 involved in myelodysplastic syndromes as a risk factor for intestinal ulcers and thrombosis--Behcet’s syndrome. Leuk Lymphoma 2001;42(1-2):115-21
   PubMed Web of Science ®Google Scholar
• Ahn JK, Cha HS, Koh EM, et al. Behcet’s disease associated with bone marrow failure in Korean patients: clinical characteristics and the association of intestinal ulceration and trisomy 8. Rheumatology 2008;47(8):1228-30
   PubMed Web of Science ®Google Scholar
• Becker K, Fitzgerald O, Green AJ, et al. Constitutional trisomy 8 and Behcet syndrome. Am J Med Genet A 2009;149A(5):982-6
   PubMed Web of Science ®Google Scholar
• Kim KJ, Kwok SK, Park YJ, et al. Low C3 levels is associated with neutropenia in a proportion of patients with myelodysplastic syndrome: retrospective analysis. Int J Rheum Dis 2012;15(1):86-94
   PubMed Web of Science ®Google Scholar
• Voulgarelis M, Giannouli S, Tasidou A, et al. Bone marrow histological findings in systemic lupus erythematosus with hematologic abnormalities: a clinicopathological study. Am J Hematol 2006;81(8):590-7
   PubMed Web of Science ®Google Scholar
• Ziakas PD, Giannouli S, Tzioufas AG, Voulgarelis M. Leukaemic synovitis. Rheumatology 2006;45(9):1143
   PubMed Web of Science ®Google Scholar
• Alessandrino EP, Della Porta MG, Bacigalupo A, et al. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 2008;112(3):895-902
   PubMed Web of Science ®Google Scholar
• George SW, Newman ED. Seronegative inflammatory arthritis in the myelodysplastic syndromes. Semin Arthritis Rheum 1992;21(6):345-54
   PubMed Web of Science ®Google Scholar
• Bagby GC Jr. The concept of preleukemia: clinical and laboratory studies. Crit Rev Oncol Hematol 1986;4(3):203-20
   PubMed Web of Science ®Google Scholar
• Epperson DE, Nakamura R, Saunthararajah Y, et al. Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res 2001;25(12):1075-83
   PubMed Web of Science ®Google Scholar
• Matsutani T, Yoshioka T, Tsuruta Y, et al. Determination of T-cell receptors of clonal CD8-positive T-cells in myelodysplastic syndrome with erythroid hypoplasia. Leuk Res 2003;27(4):305-12
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Kobayashi S, Wieder ED, et al. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 2002;100(10):3639-45
   PubMed Web of Science ®Google Scholar
• Atoyebi W, Bywater L, Rawlings L, et al. Treatment of myelodysplasia with oral cyclosporin. Clin Lab Haematol 2002;24(4):211-14
   PubMedGoogle Scholar
• Sloand EM, Wu CO, Greenberg P, et al. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008;26(15):2505-11
   PubMed Web of Science ®Google Scholar
• Passweg JR, Giagounidis AA, Simcock M, et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care – SAKK 33/99. J Clin Oncol 2011;29(3):303-9
   PubMed Web of Science ®Google Scholar
• Maciejewski J, Selleri C, Anderson S, Young NS. Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 1995;85(11):3183-90
   PubMed Web of Science ®Google Scholar
• Boula A, Voulgarelis M, Giannouli S, et al. Effect of cA2 anti-tumor necrosis factor-alpha antibody therapy on hematopoiesis of patients with myelodysplastic syndromes. Clin Cancer Res 2006;12(10):3099-108
   PubMed Web of Science ®Google Scholar
• Baron F, Suciu S, Amadori S, et al. Value of infliximab (Remicade(R)) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group. Haematologica 2012;97(4):529-33
   PubMed Web of Science ®Google Scholar
• Raza A, Candoni A, Khan U, et al. Remicade as TNF suppressor in patients with myelodysplastic syndromes. Leukemia & lymphoma 2004;45(10):2099-104
   PubMed Web of Science ®Google Scholar
• Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007;8(4):345-50
   PubMed Web of Science ®Google Scholar
• Kordasti SY, Afzali B, Lim Z, et al. IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol 2009;145(1):64-72
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10(3):223-32
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010;28(4):562-9
   PubMed Web of Science ®Google Scholar
• Lal G, Zhang N, van der Touw W, et al. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol 2009;182(1):259-73
   PubMed Web of Science ®Google Scholar
• Sanchez-Abarca LI, Gutierrez-Cosio S, Santamaria C, et al. Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood 2010;115(1):107-21
   PubMed Web of Science ®Google Scholar
• Giannouli S, Tzoanopoulos D, Ritis K, et al. Autoimmune manifestations in human myelodysplasia: a positive correlation with interferon regulatory factor-1 (IRF-1) expression. Ann Rheum Dis 2004;63(5):578-82
   PubMed Web of Science ®Google Scholar
• Maratheftis CI, Giannouli S, Spachidou MP, et al. RNA interference of interferon regulatory factor-1 gene expression in THP-1 cell line leads to Toll-like receptor-4 overexpression/activation as well as up-modulation of annexin-II. Neoplasia 2007;9(12):1012-20
   PubMed Web of Science ®Google Scholar
• Jung YO, Cho ML, Lee SY, et al. Synergism of toll-like receptor 2 (TLR2), TLR4, and TLR6 ligation on the production of tumor necrosis factor (TNF)-alpha in a spontaneous arthritis animal model of interleukin (IL)-1 receptor antagonist-deficient mice. Immunol Lett 2009;123(2):138-43
   PubMed Web of Science ®Google Scholar
• Zhou L, Opalinska J, Verma A. p38 MAP kinase regulates stem cell apoptosis in human hematopoietic failure. Cell cycle 2007;6(5):534-7
   PubMed Web of Science ®Google Scholar
• Oukka M. Interplay between pathogenic Th17 and regulatory T cells. Ann Rheum Dis 2007;66(Suppl 3):iii87-90
   PubMedGoogle Scholar
• Silverman LR, Greenberg P, Raza A, et al. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy. Hematol Oncol 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Olnes MJ, Shenoy A, Weinstein B, et al. Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. Leuk Res 2012;36(8):982-9
   PubMed Web of Science ®Google Scholar
• Paulson RF. Targeting a new regulator of erythropoiesis to alleviate anemia. Nat Med 2014;20(4):334-5
   PubMed Web of Science ®Google Scholar
• Follo MY, Mongiorgi S, Bosi C, et al. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. Cancer Res 2007;67(9):4287-94
   PubMed Web of Science ®Google Scholar
• Yurchenko E, Shio MT, Huang TC, et al. Inflammation-driven reprogramming of CD4+ Foxp3+ regulatory T cells into pathogenic Th1/Th17 T effectors is abrogated by mTOR inhibition in vivo. PLoS One 2012;7(4):e35572
   PubMed Web of Science ®Google Scholar
• de Latour RP, Visconte V, Takaku T, et al. Th17 immune responses contribute to the pathophysiology of aplastic anemia. Blood 2010;116(20):4175-84
   PubMed Web of Science ®Google Scholar